<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777062</url>
  </required_header>
  <id_info>
    <org_study_id>808641</org_study_id>
    <secondary_id>5P50DA012756-10</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00777062</nct_id>
  </id_info>
  <brief_title>VIVITROL as a Treatment for Cocaine and Alcohol Dependence</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of VIVITROL (naltrexone for extended-release injectable suspension)
      for the treatment of co-occurring cocaine and alcohol dependence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II double-blind randomized controlled clinical pilot study. The exploratory
      objectives in the proposed study will be examined with a 2-group design to assess the
      efficacy of naltrexone extended-release injectable suspension (VIVITROL™) as compared to
      placebo. Safety measures will be collected weekly through medical management (MM) by medical
      practitioners, including adverse events and concomitant meds. The psychosocial treatment will
      be Cognitive Behavioral Coping Skills Therapy (CBT). Subjects will be 80 men and women with
      current DSM-IV diagnoses of alcohol dependence and cocaine dependence that will be randomized
      to receive either VIVITROL or placebo (40 subjects per group). All subjects will receive
      weekly sessions of CBT and MM. The study length for each subject is comprised of 1-3 weeks of
      screening, an 8-week double-blind, placebo-controlled trial with MM and CBT (medication
      phase), and an end of medication visit.

      Primary Exploratory Objectives:

        -  To compare medication groups' rates of cocaine abstinence, as determined by urine assay
           for benzoylecgonine (BE), the primary metabolite of cocaine. This will be cross-checked
           against participants' self-reports of cocaine use through Time-Line Follow Back
           (TLFB)(Sobell &amp; Sobell, 1992).

        -  To compare medication groups' rates of abstinence from drinking, and of clinically
           significant drinking, as measured by the TLFB.

      Secondary Exploratory Objectives:

        -  To evaluate medication groups' reports of craving for cocaine and alcohol, as measured
           by scores on the Penn Alcohol Craving Scale and the Minnesota Cocaine Craving Scale
           during the medication treatment phase.

        -  To compare women's reports of medication tolerance of naltrexone extended-release
           injectable suspension versus high dose oral naltrexone that was reported in our recently
           published pilot trial of high dose naltrexone for dual cocaine and alcohol dependence
           (Pettinati et al., 2008).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine.</measure>
    <time_frame>8 week medication phase</time_frame>
    <description>Percentage of subjects with no cocaine use for at least 3 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Line Follow Back -Reported Days of Abstinence From Drinking</measure>
    <time_frame>8 week medication phase</time_frame>
    <description>Percentage of participants who were abstinent from drinking</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIVITROL (Naltrexone extended-release injectable suspension)</intervention_name>
    <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection at the start of weeks 2 and 6.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Males and females, 18 to 65 years old.

          2. Meets DSM-IV criteria for Cocaine Dependence, as determined by the Structured Clinical
             Interview for DSM-IV (SCID).

          3. Meets DSM-IV criteria for Alcohol Dependence, as determined by the Structured Clinical
             Interview for DSM-IV (SCID).

          4. Meets the following drinking criteria as measured by the Timeline Followback (TLFB)
             (Sobell, 1995)

               1. drank within 30 days of intake day,

               2. reports a minimum of XX standard alcoholic drinks in a consecutive 30-day period
                  over the 90-day period prior to starting intake, and

               3. has 2 or more days of heavy drinking

          5. In the past 30 days prior to consent, used no less than $ of cocaine.

          6. Live within a commutable distance of the Treatment Research Center (TRC) at the
             Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to
             be a distance within the service area of Septa, within an hour drive, or a distance
             that both the patient and Principal Investigator (PI) find acceptable.

          7. Understands and signs the informed consent.

          8. Three consecutive days of abstinence from alcohol, and a Clinical Institute Withdrawal
             Scale for Alcohol (CIWA-AR) (Sullivan, 1989) score below eight.

        4.2 Exclusion Criteria:

          1. Positive urine drug screen and/or current DSM-IV diagnosis of any psychoactive
             substance dependence other than cocaine, alcohol, or nicotine dependence, as
             determined by the SCID.

          2. Concomitant treatment with psychotropic medications, including opioid analgesics.

          3. Patients mandated to treatment based upon a legal decision or as a condition of
             employment.

          4. Current severe psychiatric symptoms, e.g., psychosis, dementia, suicidal or homicidal
             ideation, mania or depression requiring antidepressant therapy in the opinion of the
             Principal Investigator (PI).

          5. Taken any investigational medication within the past 30 days.

          6. History within the six months prior to randomization of significant heart disease (an
             arrhythmia which required medication, Wolff-Parkinson-White Syndrome, angina pectoris,
             documented history of myocardial infarction, heart failure). These are to be reviewed
             on a case-by-case basis: EKG 1st degree heart block, sinus tachycardia, left axis
             deviation, and nonspecific ST or T wave changes are allowed; liver function tests
             [LFTs] &lt;3 x ULN are acceptable).

          7. Known hypersensitivity to naltrexone, PLG, carboxymethylcellulose, or any other
             components of the diluent.

          8. Subjects with a BMI of 40 and above, as determined by the Body Mass Index Table, or
             that have distribution of adipose tissue such that they would be at greater risk of
             serious injection site reaction, based on clinical judgment. Participants with a BMI
             over 30 will have additional screening procedures conducted to determine inclusion in
             the study. These procedures include an additional screening measurement of waist-hip
             ratio for those participants with a BMI over 30. Males with a waist to hip ratio of
             &gt;0.9 and females with a waist to hip ratio of &gt;0.85 will be referred to the
             investigator for final decision of study inclusion. If the ratio is &lt;0.9 for men or
             &lt;0.85 for women they will be eligible for study inclusion without further action.

          9. Patients with any serious illnesses that may require hospitalization during the study.

         10. Female subjects who are pregnant or lactating, or female subjects of child-bearing
             potential who are not using acceptable methods of birth control. Acceptable methods of
             birth control include:

         11. Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits
             that are clinically unacceptable to the Principal Investigator.

         12. Current physiological opioid dependence.

         13. Experiencing acute opiate withdrawal.

         14. Likely to receive scheduled surgery, which may require treatment with opioid
             analgesics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Pettinati, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/csa/index.html</url>
    <description>University of Pennsylvania Center for the Studies of Addiction</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>December 12, 2013</results_first_submitted>
  <results_first_submitted_qc>December 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2014</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>alcohol</keyword>
  <keyword>cocaine</keyword>
  <keyword>addiction</keyword>
  <keyword>alcoholism</keyword>
  <keyword>substance dependence</keyword>
  <keyword>substance abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vivitrol</title>
          <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vivitrol</title>
          <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" spread="7.0"/>
                    <measurement group_id="B2" value="48.4" spread="6.3"/>
                    <measurement group_id="B3" value="47.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine.</title>
        <description>Percentage of subjects with no cocaine use for at least 3 weeks</description>
        <time_frame>8 week medication phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vivitrol</title>
            <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine.</title>
          <description>Percentage of subjects with no cocaine use for at least 3 weeks</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Line Follow Back -Reported Days of Abstinence From Drinking</title>
        <description>Percentage of participants who were abstinent from drinking</description>
        <time_frame>8 week medication phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vivitrol</title>
            <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Line Follow Back -Reported Days of Abstinence From Drinking</title>
          <description>Percentage of participants who were abstinent from drinking</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vivitrol</title>
          <description>VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo injection, 380 mg injection at the start of weeks 2 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for nausea and vomiting</sub_title>
                <description>Participant said nausea was resolved on 3/7/10 and did not receive second injection. He finished his final study visit on 4/12/10.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for pneumonia</sub_title>
                <description>Participant complained of feeling ill and very fatigued. He had a high fever on 8/5/11, so study nurse recommended that he go to the ER. He was admitted on 8/5/11 with pneumonia, and released on 8/9/11.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Worsening of addiction symptoms</sub_title>
                <description>Participant entered inpatient treatment for worsening of addiction symptoms.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lacerations and fractured rib</sub_title>
                <description>Participant was physically attacked and hospitalized for injuries.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hospitalization for an overdose of tylenol</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <description>Participant sent to dermatology clinic and they recommended monitoring the site, but no urgent action needed. Participant t finished out study visits and swelling went down.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kyle Kampman</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 109</phone>
      <email>kampman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

